BIAF
NASDAQ · Biotechnology
Bioaffinity Technologies Inc
$1.99
+0.10 (+5.29%)
Open$1.88
Previous Close$1.89
Day High$2.00
Day Low$1.87
52W High$15.00
52W Low$0.69
Volume—
Avg Volume280.9K
Market Cap9.02M
P/E Ratio—
EPS$-15.42
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,326.6% upside
Current
$1.99
$1.99
Target
$28.39
$28.39
$22.24
$28.39 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 16.24M | 608.9K | 644.1K |
| Net Income | -39,285,890 | -195,635 | -204,930 |
| Profit Margin | -242.0% | -32.1% | -31.8% |
| EBITDA | -27,744,555 | -176,028 | -183,952 |
| Free Cash Flow | — | -119,784 | -113,422 |
| Rev Growth | — | +18.5% | +20.2% |
| Debt/Equity | 0.11 | 1.28 | 1.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |